Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.73 |
| ▸ | CTSV | O60911 | 5/20 | 0.67 |
| ▸ | CTSL | P07711 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10833797 | 0.95 | SIRT2 (0.80) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL6482855 | 0.88 | SIRT2 (0.77) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL6475801 | 0.87 | MEN1 (0.79) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL6475772 | 0.86 | MEN1 (0.76) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL6475426 | 0.85 | MEN1 (0.64) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL10934405 | 0.84 | SIRT2 (0.76) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL10833856 | 0.83 | SIRT2 (0.74) | SIRT2CTSVCTSLKMT2AALDH1A1 | |
| SCHEMBL6482582 | 0.82 | PLK1 (0.64) | SIRT2MEN1KMT2ATDP1RECQL | |
| SCHEMBL6484679 | 0.81 | MEN1 (0.57) | SIRT2CTSVCTSLMEN1KMT2A | |
| SCHEMBL6475302 | 0.81 | MEN1 (0.54) | SIRT2CTSVCTSLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | claimed |
| CN-1378446-A | Method for inhibiting amyloid aggregation and imaging amyloid deposits | WARNER LAMBERT CO (US) | 2002-11-06 | — | — | CN | claimed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| CN-1378446-A | Method for inhibiting amyloid aggregation and imaging amyloid deposits | WARNER LAMBERT CO (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | SIRT2 2735/4885CTSV 2743/4885CTSL 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.